Deramciclane fumarate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561049

CAS#: 120444-72-6 (fumarate)

Description: Deramciclane fumarate is a putative anxiolytic compound, and a 5-HT(2A/C) antagonist. In rats, a single high dose of deramciclane has the neuroleptic- or buspirone-like effect, particularly in mesolimbic regions.

Chemical Structure

img
Deramciclane fumarate
CAS# 120444-72-6 (fumarate)
Instruction

Theoretical Analysis

MedKoo Cat#: 561049
Name: Deramciclane fumarate
CAS#: 120444-72-6 (fumarate)
Chemical Formula: C24H35NO5
Exact Mass: 0.00
Molecular Weight: 417.550
Elemental Analysis: C, 69.04; H, 8.45; N, 3.35; O, 19.16

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 120444-71-5 (free base)   120444-72-6 (fumarate)    

Synonym: Deramciclane fumarate; Deramciclane; EGIS 3886; EGIS-3886; EGIS3886; exo-EGYT 3886;

IUPAC/Chemical Name: N,N-dimethyl-2-(((1R,2S,4R)-1,7,7-trimethyl-2-phenylbicyclo[2.2.1]heptan-2-yl)oxy)ethan-1-amine fumarate

InChi Key: RFQWRWCCNQNACG-HJYQBBATSA-N

InChi Code: InChI=1S/C20H31NO.C4H4O4/c1-18(2)17-11-12-19(18,3)20(15-17,22-14-13-21(4)5)16-9-7-6-8-10-16;5-3(6)1-2-4(7)8/h6-10,17H,11-15H2,1-5H3;1-2H,(H,5,6)(H,7,8)/b;2-1+/t17-,19-,20+;/m1./s1

SMILES Code: O=C(O)/C=C/C(O)=O.CC1(C)[C@@]2([H])C[C@](OCCN(C)C)(C3=CC=CC=C3)[C@]1(C)CC2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 417.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Kääriäinen TM, Lehtonen M, Forsberg MM, Savolainen J, Käenmäki M, Männistö PT. Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats. Basic Clin Pharmacol Toxicol. 2008 Jan;102(1):50-8. Epub 2007 Oct 25. PubMed PMID: 17971064.

2: Al-Behaisi S, Antal I, Morovján G, Marton S, Klebovich I. The effect of oil as a dietary component on in vitro dissolution of an acid-labile drug. Pharmazie. 2003 Jul;58(7):502-3. PubMed PMID: 12894756.

3: Nemes KB, Abermann M, Bojti E, Grézal G, Al-Behaisi S, Klebovich I. Oral, intraperitoneal and intravenous pharmacokinetics of deramciclane and its N-desmethyl metabolite in the rat. J Pharm Pharmacol. 2000 Jan;52(1):47-51. PubMed PMID: 10716602.

4: Ladányi L, Sztruhár I, Budai Z, Lukács G, Mezei T, Argay G, Kálmán A, Simig G. Stereochemistry and enantiomeric purity of a novel anxiolytic agent, deramciclane fumarate. Chirality. 1999;11(9):689-93. PubMed PMID: 10506429.

5: Kanerva H, Vilkman H, Någren K, Kilkku O, Kuoppamäki M, Syvälahti E, Hietala J. Brain 5-HT2A receptor occupancy of deramciclane in humans after a single oral administration--a positron emission tomography study. Psychopharmacology (Berl). 1999 Jul;145(1):76-81. PubMed PMID: 10445375.

6: Lengyel J, Bolehovszky A, Klebovich I, Aberman M, Magyar K. Absorption of the new anxiolytic compound deramciclane in rats, dogs and rabbits. Arzneimittelforschung. 1998 May;48(5):455-60. PubMed PMID: 9638311.